
The C-Trap® provides the world’s first dynamic single-molecule microscope to allow simultaneous manipulation and visualization of single-molecule interactions in real time.

90% of immuno-oncology drugs entering Phase I clinical trials fail, due to a poor predictive value of current preclinical assays. To solve this, scientists and drug developers are turning to Cell Avidity, the total binding strength between cells, to better predict therapeutic efficacy.
Join us for an exclusive virtual demonstration of Avidion, the next generation of Cell Avidity technology. This session isdesigned for researchers and groups who understand the "why" of avidity but want to see the "how."
We will take you inside the instrument to explore the automated workflow, preview our intuitive software interface, and show real-world customer proof that validates its predictive power. See how Avidion transforms complexcellular interactions into actionable insights with push-button simplicity.
We know your time is valuable, that's why we designed this 30-minute intensive session specifically for researchers who need to seethe technology in action. Don’t miss your chance to talk directly with LUMICKS scientists and product managers. See the future of cell interaction analysis from your desk.
T cells play a pivotal role in tumor immunosurveillance. Multispecific cell engagers (CEs) have been adopted in the field of immuno-oncology to redirect T cells toward cancer cells, thereby unleashing the anti-tumor potential of the patient’s immune system. CE-mediated cell binding induces T cell activation and the formation of an immunological synapse, which is a prerequisite for effective tumor cell lysis.
The strength of the initial binding events between a T cell and a tumor cell dictates the efficiency of the anti-tumor response. Assessing cell avidity, i.e. the total intercellular interaction strength between two cells, gives crucial insights into the efficacy of CEs as anti-tumor therapeutic agents.
Here, we deploy LUMICKS’ high throughput avidity measurement (HTAM) technology to measure CE-induced cell avidity in a high throughput manner. We demonstrate the assay performance characteristics, i.e. specificity, precision, and range, via CE titration experiments in the context of a Jurkat T cell model system. We find that the HTAM CA assay is suitable for candidate screening in high throughput, with high sensitivity and precision.